NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
ASX · SLD.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 05:11 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Saluda Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.11% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Saluda Medical, Inc.’s next earnings report is currently expected on Mar 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Saluda Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Saluda Medical, Inc., a medical device company, develops treatments for chronic neurological conditions in the United States, Australia, Europe, and internationally. The company offers a closed-loop, dose-control platform which senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. It provides Evoke, an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. The company was founded in 2011 and is based in Bloomington, Minnesota.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:28 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$410.91+$3.81 (+0.94%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 10.99% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$460.73+$8.90 (+1.97%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
A$0.13+A$0.01 (+8.33%)
EBR Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.6% below the high.
